Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS

v3.3.0.814
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2015
Related Party Transactions [Abstract]  
Related Party Transactions Disclosure [Text Block]
9.  RELATED PARTY TRANSACTIONS
 
The Company’s chief scientific officer and principal founder of Cellectar, who is a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”).  During the nine months ended September 30, 2015, the Company was invoiced $479,496 by UW, of which $460,356 has been paid, for costs associated with clinical trial agreements